VANCOUVER and TORONTO, Canada (November 3, 2016) — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, announced it has received a $525,000 investment from Canadian partners: Accel-Rx Health Sciences Accelerator, The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI).
This unique deal brings together three organizations mandated with enabling the growth of Canada’s health sciences sector. Each partner brings its respective strengths to the table: capital, ...
This new license is an important step forward in bringing a new drug therapy closer to patients living with diabetes as it will enable us to access a promising lead drug candidate and position us to start clinical trials as early as 2018.
Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to prevent hypoglycemia in patients with diabetes, has signed a licensing agreement with The Centre for Drug Research and Development (CDRD) for access to a ...
XOR-Labs Toronto (XOR) a spin-oXOR-Labs Toronto (XOR) a spin-off from Toronto General Hospital at University Health Network today announced the closing of another financing through a private placement, led by lead investor Regenesis Limited Partnership, along with the participation of its existing investors, including Xenios AG and MaRS Innovation. The total raised in this round is CAN$2.85M. This is a solid vote of confidence and the second investment in XOR for Xenios which invested an additional CAN$2.6M in the company in ...
Toronto, August 18, 2016 – Toronto-based ScarX Therapeutics (ScarX) has received approval from Health Canada to begin a Phase I clinical trial of its SCX-001 nefopam cream, a first-of-its-kind topical treatment developed to significantly reduce surgical scarring.
This announcement was covered in Yahoo Finance, The Canadian Business Journal, Global News Wire, and BioSpace.
Applied immediately after surgical wound closure, SCX-001 reduces the amount of scar tissue that develops during the body’s natural healing process. The 24-subject Phase I clinical trial will be conducted at ...
UTEST graduate company building a versatile, smart, modular power bar
We've all been there: You reach over behind your TV to plug in yet another device to find your power bar’s out of available outlets. You wonder why your electricity bill’s so high and want to know which appliance is the culprit. You forget to turn something off (or did you?) and you’re already halfway to a meeting.
Knitt Labs, Inc. has developed KnittBar to solve these frustrating problems for those who are ...
TORONTO and SAN DIEGO (June 4, 2016) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced positive results from its Phase 1 proof-of-concept study evaluating marizomib in combination with bevacizumab in patients with WHO grade IV malignant glioma.
These results were presented in a poster session during the American Society for Clinical Oncology (ASCO) annual meeting in Chicago on June 4, 2016.
“These results confirm our original hypothesis that this combination therapy is ...
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published the following guest column by Dr. Raphael Hofstein, MaRS Innovation’s president & CEO, and Elizabeth Monier-Williams, director of marketing and communications.
There’s a historical trend in Canadian culture with far-reaching effects for the way we do business, ranging from entertainment to academia to science. Namely, it’s that until quite recently, Canadians weren’t into cultivating national star systems. 
As Gideon Hayden recently wrote for TechCrunch, if you’re a Canadian tall poppy ...